Bank of America Corp DE increased its stake in Black Diamond Therapeutics (BDTX) by 76.7% in Q4, while other hedge funds also adjusted their holdings. Research analysts raised BDTX's rating and target price, and a major shareholder sold a significant portion of shares, reducing their ownership. The company's stock has a market cap of $131.35M and is focused on oncology drug development.

Wellington Management Group LLP increased its stake in Black Diamond Therapeutics (BDTX) by 7.9% in Q4, while other institutional investors also adjusted their positions. The company reported Q1 earnings of -$0.28 EPS, exceeding analyst estimates. Insider activity included a significant sale by Growth N.V. Biotech, and analysts issued mixed ratings. BDTX, a clinical-stage oncology biotech, focuses on developing MasterKey therapies for tumors with specific genetic markers.

Black Diamond Therapeutics, a clinical-stage oncology company, reported first-quarter 2025 financial results, including a net income of $56.5 million, and provided updates on its Phase 2 trial for BDTX-1535 and a global licensing agreement with Servier for BDTX-4933. The company highlighted progress in clinical trials, a strong cash position, and upcoming regulatory feedback.

Black Diamond (BDI) reported record revenue and EBITDA in Q1 2025, with a 287% profit increase to $5.8 million and a 39% revenue surge to $102.2 million. The company highlighted strong performance in its MSS segment, improved return on assets, and a healthy balance sheet, despite challenges in the WFS and LodgeLink segments.

Black Diamond Capital Management L.L.C. increased its stake in Wynn Resorts, Limited (NASDAQ:WYNN) by 10.3% during the 4th quarter, now holding 107,012 shares valued at $9.22 million. Other institutional investors also adjusted their positions, while insiders executed significant share purchases. Wynn Resorts reported strong quarterly earnings and received analyst upgrades, with a market cap of $8.73 billion.